J&J | JNJ - Net Income


J&J reported $5.53B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Abbott USD 928M 149M Jun/2026
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Baxter International USD 126M 141M Jun/2026
Bayer EUR 219M 2.54B Jun/2026
Becton, Dickinson and Co. USD 377M 688M Jun/2026
Biogen USD 97.5M 222M Jun/2026
Boston Scientific USD 907M 434M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
CONMED USD 23.07M 9.24M Jun/2026
Cooper Companies USD 432.8M 510.7M Jun/2026
Dexcom USD 249.1M 49.6M Jun/2026
Edwards Lifesciences USD 241.9M 138.8M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Globus Medical USD 151.57M 27.27M Jun/2026
Insulet USD 95M 3.9M Jun/2026
Integra LifeSciences USD 4.48M 9.1M Jun/2026
Intuitive Surgical USD 818.1M 3.4M Jun/2026
J&J USD 5.53B 299M Jun/2026
Medtronic USD 1.47B 227M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Merit Medical Systems USD 41M 2.99M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Stryker USD 1.28B 531M Jun/2026
Tandem Diabetes Care USD -21.17M 775K Jun/2026
Teva Pharmaceutical Industries USD -576M 945M Jun/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026
Zimmer Biomet Holdings USD 198.3M 39.8M Jun/2026
Zoetis USD 691M 90M Jun/2026